JESSICA DAVIS: Open Payments
NPI 1528215076 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$407 in 18 payments from 9 companies in 2025. Trend: 2023 $386 · 2024 $777 · 2025 $407
Food & beverage: $407
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 4 | $94 |
| EMD Serono, Inc. | 3 | $78 |
| Adaptive Biotechnologies Corporation | 2 | $50 |
| Melinta Therapeutics, LLC | 2 | $43 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| Agios Pharmaceuticals, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Janssen Biotech, Inc. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: Xtandi, clonoSEQ, Rezzayo, PYRUKYND, Padcev, GIVLAARI, SCEMBLIX, CARVYKTI.
Industry payments across CA — which companies pay providers there.
